Analyzing the stock…
70
Gathering technical, fundamental, and market data — a few seconds
Health Care · ·
$2.92
▼ $0.15 (-4.9%)
Market data updated: 09/27 11:41 PM
Fundamentals updated: 09/27/2026
News analyzed: 09/27/2026
Market Cap
$69.51M
Day Range
$2.91 - $3.09
52-Week Range
$2.91 - $11.88
Beta
—
Next Earnings
10.11.2026
Support
$2.91
Resistance
$6.25
KLRS is a stock from the Healthcare sector — Pharmaceuticals, biotech, medical devices, and health insurance — less sensitive to economic cycles, but exposed to regulation and FDA approvals.
-38.8% (1Y)
Strengths: 5/23 factors positiveRisk: High
This score and all analysis on this page are for informational and educational purposes only and do not constitute investment advice. Read the full disclaimer
Weighted: Technical 25% · Fundamental 20% · Growth 15% · Valuation 15% · News 10% · Quality 10% · Risk 5%
Overall Score
🔴 Bearish
Technical Trend
🔴 Bearish
Insiders
🟢 Bullish
Computed directly from the same signals behind the score above — not AI-generated.
Biggest positive driver
Earnings per share (EPS) growth
Earnings per share (EPS) growth: 94.5%
Growth
Biggest negative driver
Daily volatility (ATR)
ATR: 7.2% of price
Risk
What to watch next
When today echoes the past.
NO RELIABLE ECHO FOUND
Only 3 historical analog(s) found after removing overlapping dates — too few for a statistically meaningful comparison.
Historical matches considered: 3
TIME ECHO identifies historical situations that resemble the current market state. Historical outcomes are not guarantees of future performance. Similarity does not imply causation, and results may change as new data becomes available.
🗓️ What Changed This Week
🌱 Building History
We don't have a real data point from a week ago for this stock yet. The weekly comparison will appear once enough history has accumulated.
📊 Score History
41
Today
—
30D
—
90D
—
1Y
🕰️ Signal Timeline
What StockIQ actually saw for this stock, and what happened after each signal — real data, not a forecast.
today · $2.92
Evidence: Panic-selling score jumped from 5 to 41 day-over-day
What happened after
Still awaiting outcome
🐂🐻 Investment Thesis
🐂 Bull Case
🐻 Bear Case
🔍 What Could Prove This Wrong
This isn't a price-direction forecast — just a synthesis of real, already-computed data, and future conditions that could change the picture.
🧬 STOCK DNA
This stock's profile across 8 real dimensions — a research tool, not a recommendation
Growth
66
Quality
No data available
Value
55
Momentum
6
Risk
40
Sentiment
74
Fundamental
41
Institutional
100
Stocks with a similar DNA right now
This stock hasn't been analyzed by StockIQAI's movement engine yet — coverage is still expanding. Check back soon.
Recent media coverage of Kalaris Therapeutics has highlighted its progress in clinical trials and leadership changes. The company reported positive Phase 1a trial results for its drug TH103 in neovascular age-related macular degeneration (AMD), showing improved vision in additional patients. Additionally, Kalaris announced financial updates for Q2 2026, including reduced losses per share, and named Liisa Bayko as its new CFO while appointing Laurie Keating to its board. The company also confirmed its participation in the Morgan Stanley Healthcare Conference.
AI summary based on English-language news sources only — not investment advice.
Everyone's writing about Kalaris Therapeutics, Inc.. News trend score: 74. Reason: 4 of the last 13 articles are positive, versus 0 negative.
News trend analysis is based on article sentiment only, and is not investment advice or financial counsel. Read the full disclaimer
🌡️ Emotional Temperature
34
🎯 Conviction (vs. Emotion)
50
Psychology
95
Fundamentals
41
Technical
6
Valuation
55
A significant decline over time, but on unusually low trading volume — holders unwilling to accept the loss.
The price is holding at a real, documented historical support/resistance level (a 50-day high or low).
The stock is moving in lockstep with its peers at the same intensity, rather than on its own data.
A sharp drop, unusual volume, and negative news sentiment all at once — selling pressure that looks emotional.
Extreme momentum, price far above its moving average, and a large premium over fair value.
Price (3M)
-32%
Market Narrative
42
Fundamental Reality
50
Narrative Gap
-8
🔀 Psychology Acceleration
News attention/sentiment is running well ahead of the price move itself.
🧠 StockIQ Psychologist
The dominant Loss Aversion (57) reflects a market behavior consistent with recent underperformance (-12.2% over three months) and subdued trading activity (0.71x average volume). Herding (46) suggests cautious alignment with peer declines, though the stock underperformed slightly today. The narrative gap (-4) hints at a mild disconnect between market sentiment and fundamentals, but no extreme bias is active. The key open question is whether the muted volume and lack of volatility (0.74x ATR) signal hesitation or a temporary pause in selling pressure.
Updated: 09/08/2026, 12:47 AM
What could change this?
👥 What the crowd believes
"Kalaris Therapeutics Names Liisa Bayko CFO (Article 4)"
"Additional Patients Show Improved Vision in Phase 1a Trial in Neovascular AMD (Article 7)"
"TD Cowen Initiates Kalaris Therapeutics at Buy (Article 12)"
"quarterly losses of $(0.48) per share which beat the analyst consensus estimate (Article 3)"
🧠 Market Brain events driving this
Signal classification confidence: High (confidence in the behavioral read, not a price prediction). Describes observable market behavior, not what any individual investor thinks, and is not a buy/sell signal.
🏛️ Investor DNA — Historical Investors
A Historical Strategy Simulation: assuming each investor follows their documented principles, how would they rate this stock today? This is not a prediction of what they would actually do.
🟢 Best match
Benjamin Graham — 100/100
🔴 Weakest match
Morgan Housel — 0/100
🗣️ Why do they disagree?
This stock sparks a sharp divide between value-focused and cyclical methodologies, with Graham’s school overwhelmingly bullish while behavioral and market-efficiency frameworks dismiss it outright. Benjamin Graham and his Enterprising Investor variant both see deep statistical discounts, while Samuel Nelson’s cycle analysis flags it as oversold—suggesting a contrarian opportunity. In contrast, Howard Marks (market cycle) and Walter Bagehot still view it favorably, though Marks’ broader perspective warns of potentially inflated expectations. Meanwhile, the efficient-market camp and Morgan Housel’s volatility-aware approach reject it entirely, with Housel’s zero score implying it’s too risky for patient long-term holders, while Livermore’s trend-following rule outright condemns it. The disconnect highlights how value investors prioritize fundamentals and cycles, while trend-followers and index advocates prioritize macro signals or risk aversion.
Benjamin Graham
Security Analysis (1934) / The Intelligent Investor (1949)
🟢 100
Attractive to a Defensive Graham Investor
Key question
Where is my margin of safety?
⚠️ Partial data for this stock — score is less reliable — Data availability: 35%
Fact → Principle → Simulation
Peter Lynch
One Up on Wall Street (1989)
🟢 100
Not enough growth data for a real Lynch read
Key question
Is the growth worth the price?
⚠️ Partial data for this stock — score is less reliable — Data availability: 25%
Fact → Principle → Simulation
Samuel Armstrong Nelson
The ABC of Stock Speculation (1903)
🟢 98
Cycle position looks favorable — closer to oversold than overbought
Key question
Is the price overextended, or is there still room to move?
Fact → Principle → Simulation
Benjamin Graham (Enterprising Investor)
The Intelligent Investor (1949) — the Enterprising Investor chapters
🟢 98
Deep statistical discount — a real Enterprising Investor candidate
Key question
Is the stock statistically cheap enough to justify the extra risk?
⚠️ Partial data for this stock — score is less reliable — Data availability: 45%
Fact → Principle → Simulation
Howard Marks (Market Cycle)
Mastering the Market Cycle (2018)
🟢 87
Looks early-to-mid cycle, not overextended
Key question
Where are we in the cycle right now — near a hot extreme, or a cold one?
Fact → Principle → Simulation
Charles Mackay
Extraordinary Popular Delusions and the Madness of Crowds (1841)
🟢 86
No obvious signs of crowd mania
Key question
Am I being swept along with the crowd, or thinking for myself?
Fact → Principle → Simulation
Walter Bagehot
Lombard Street (1873)
🟢 73
Strong liquidity — would likely survive a real credit squeeze
Key question
Does this company have enough liquidity to survive real stress?
Fact → Principle → Simulation
Jack Schwager
Market Wizards (1989)
🟡 64
No clear edge either way
Key question
What's the risk/reward here, and where is my exit point?
Fact → Principle → Simulation
Howard Marks
The Most Important Thing (2011) / Mastering the Market Cycle (2018)
🟡 58
Mixed — a good business, but expectations may already be high
Key question
What is the market probably misunderstanding about the risk here?
Fact → Principle → Simulation
Thorstein Veblen
The Theory of Business Enterprise (1904)
🟡 53
Mixed signal on whether growth translates to real profit
Key question
Is management building real value, or just building itself?
⚠️ Partial data for this stock — score is less reliable — Data availability: 45%
Fact → Principle → Simulation
Philip Fisher
Common Stocks and Uncommon Profits (1958)
🟡 50
Not enough fundamentals data for a real Fisher read
Key question
How exceptional is this business, really?
⚠️ Partial data for this stock — score is less reliable — Data availability: 0%
Gerald M. Loeb
The Battle for Investment Survival (1935)
🟡 39
Risk profile Loeb would flag as a real threat to capital
Key question
How much capital could I lose here if I'm wrong?
Fact → Principle → Simulation
Burton Malkiel & John Bogle
A Random Walk Down Wall Street (1973) / The Little Book of Common Sense Investing (2007)
🟡 37
Mixed case — the evidence for picking this stock over an index is not strong
Key question
Do I actually have an edge here, or do I just think I do?
Fact → Principle → Simulation
Jesse Livermore
Reminiscences of a Stock Operator (1923) / How to Trade in Stocks (1940)
🔴 16
Negative trend — against Livermore's core rule of trading with the trend
Key question
What is the price telling me right now?
Fact → Principle → Simulation
Edgar Lawrence Smith
Common Stocks as Long-Term Investments (1924)
🔴 15
Not enough dividend/growth data for a real Smith read
Key question
Is this a stock I'd be happy to hold and forget about for a decade?
⚠️ Partial data for this stock — score is less reliable — Data availability: 25%
Fact → Principle → Simulation
Morgan Housel
The Psychology of Money (2020)
🔴 0
The kind of volatility that tends to shake patient holders out
Key question
Could I live with this volatility long enough for compounding to actually work?
⚠️ Partial data for this stock — score is less reliable — Data availability: 30%
Fact → Principle → Simulation
Based on the last 286 trading days, calculated from real price data. Click an indicator for details and a chart.
🔴 Most indicators support a downtrend (0 bullish · 11 bearish · 0 neutral)
A market-structure read based purely on real price and volume data — not full classic Wyckoff schematic identification (Phase A-E), but a quantitative analysis of what can reliably be computed: trading ranges, "effort vs. result", volume within the range, and Spring/Upthrust detection.
The stock is in a clear downtrend with no defined trading range in the period examined.
High confidence
The Wyckoff Method, developed by Richard Wyckoff in the early 20th century, reads the balance of supply and demand through price and volume, based on the premise that large investors ("smart money") quietly accumulate shares before rallies and quietly distribute them before declines. The read here is based solely on real price and volume data — full, precise identification of classic Wyckoff patterns (such as Phases A-E) requires human chart-reading experience and judgment, so this is an approximate algorithmic read, not a substitute for professional analysis. This should not be considered investment advice.
Gross Margin
—
Operating Margin
—
Net Margin
—
EBITDA Margin
—
ROE
-55.1%
ROA
-35.7%
ROIC
—
EPS
-$2.85
Cash
$98.05M
Total Debt
—
Current Ratio
12.23
Debt/Equity
—
אין נתונים היסטוריים זמינים.
How is Fair Value calculated? →
Current Price
$2.92
Estimated Fair Value (DCF)
-$47.13
Model estimate — not a price target. Highly sensitive to growth/discount-rate assumptions.
Gap
⚠️ Extreme
Model output is extreme — likely a data/model limitation for this stock, not a reliable fair-value read.
Year 1 Growth Rate
10.0%
Discount Rate (WACC)
9.0%
Terminal Growth Rate
2.5%
Projection Years
5
| Year | Growth Rate | Projected FCF | Present Value |
|---|---|---|---|
| 1 | 10.0% | $-42.43M | $-38.92M |
| 2 | 8.1% | $-45.87M | $-38.61M |
| 3 | 6.3% | $-48.74M | $-37.64M |
| 4 | 4.4% | $-50.87M | $-36.04M |
| 5 | 2.5% | $-52.15M | $-33.89M |
Base FCF (last actual year)
$-38.57M
Terminal Value
$-822.30M
Present Value of Terminal Value
$-534.44M
Enterprise Value
$-719.54M
Net Debt
$0
Equity Value
$-719.54M
*The DCF model is an estimate based on assumptions — not a guaranteed forecast. You can change the assumptions to examine different scenarios.
Book Value per Share
$5.16
Tangible Book Value per Share (Tangible NAV)
$5.16
Sentiment based on basic keywords (not AI) — 4 positive, 9 neutral, 0 negative out of the last 13 articles.
Yahoo · 31.8.2026
GlobeNewswire · 31.8.2026
GlobeNewswire · 11.8.2026
Benzinga · 11.8.2026
MT Newswires · 20.7.2026
GlobeNewswire · 20.7.2026
MT Newswires · 17.7.2026
MT Newswires · 17.7.2026
GlobeNewswire · 17.7.2026
Insider Monkey · 14.7.2026
GlobeNewswire · 6.7.2026
GlobeNewswire · 23.6.2026
MT Newswires · 15.6.2026
Kalaris Therapeutics, Inc. (KLRS) currently has a StockIQ AI score of 41/100, rated "Weak" (a partial score — based on only 6 of 7 categories, some data is currently unavailable). The score is a weighted average across up to 7 categories (technical, fundamental, growth, fair value, news, quality, risk), based on real data only.
KLRS currently scores 41/100 (Weak) across the categories we measure (a partial score — based on only 6 of 7 categories, some data is currently unavailable). StockIQ doesn't give buy/sell recommendations — use this as one data point in your own research, not as investment advice.
KLRS's technical score is 6/100, which currently reads as bearish — based on real price/volume signals (moving averages, RSI, MACD, and more), not a prediction of what happens next.
Based on the real signals StockIQ computed: Earnings per share (EPS) growth: 94.5%; Net income growth: 37.2%; Current ratio: 12.23.
Based on the real signals StockIQ computed: ATR: 7.2% of price; Calmar: -0.64 (3y annualized return -61.8% / max drawdown 95.9%); Return on equity (ROE): -55.1% (negative).
StockIQ has no recorded dividend payment history for KLRS.
Real transactions by officers and insiders, as reported to the SEC on Form 4 — 2 purchases and 0 sales out of the last 25 filings.
| Name | Transaction Type | Date | Shares | Change | Price |
|---|---|---|---|---|---|
| Vandekop Amy O'Leary | Grant/Award from Employer | 27.8.2026 | 10,000 | +10,000 | — |
| Vandekop Amy O'Leary | Grant/Award from Employer | 27.8.2026 | 10,000 | +10,000 | — |
| KEATING LAURIE | Grant/Award from Employer | 1.8.2026 | 18,000 | +18,000 | — |
| KEATING LAURIE | Grant/Award from Employer | 1.8.2026 | 18,000 | +18,000 | — |
| Bayko Liisa Ann | Grant/Award from Employer | 20.7.2026 | 220,000 | +220,000 | — |
| Bayko Liisa Ann | Grant/Award from Employer | 20.7.2026 | 220,000 | +220,000 | — |
| Dybbs Michael | Grant/Award from Employer | 3.6.2026 | 9,000 | +9,000 | — |
| PATTERSON LEONE D | Grant/Award from Employer | 3.6.2026 | 9,000 | +9,000 | — |
| Hallal David | Grant/Award from Employer | 3.6.2026 | 9,000 | +9,000 | — |
| Jovan-Embiricos Morana | Grant/Award from Employer | 3.6.2026 | 9,000 | +9,000 | — |
| AKKARAJU SRINIVAS | Grant/Award from Employer | 3.6.2026 | 9,000 | +9,000 | — |
| Ferrara Napoleone | Grant/Award from Employer | 3.6.2026 | 9,000 | +9,000 | — |
| ADAMIS ANTHONY P | Grant/Award from Employer | 3.6.2026 | 9,000 | +9,000 | — |
| PATTERSON LEONE D | Grant/Award from Employer | 3.6.2026 | 9,000 | +9,000 | — |
| AKKARAJU SRINIVAS | Grant/Award from Employer | 3.6.2026 | 9,000 | +9,000 | — |
| ADAMIS ANTHONY P | Grant/Award from Employer | 3.6.2026 | 9,000 | +9,000 | — |
| Hallal David | Grant/Award from Employer | 3.6.2026 | 9,000 | +9,000 | — |
| Jovan-Embiricos Morana | Grant/Award from Employer | 3.6.2026 | 9,000 | +9,000 | — |
| Dybbs Michael | Grant/Award from Employer | 3.6.2026 | 9,000 | +9,000 | — |
| Ferrara Napoleone | Grant/Award from Employer | 3.6.2026 | 9,000 | +9,000 | — |
| AKKARAJU SRINIVAS | Other Transaction | 20.5.2026 | 14,937 | +14,937 | — |
| AKKARAJU SRINIVAS | Other Transaction | 20.5.2026 | 4,471 | +4,471 | — |
| AKKARAJU SRINIVAS | Open Market Purchase | 20.5.2026 | 244,300 | +244,300 | $4.83 |
| AKKARAJU SRINIVAS | Other Transaction | 20.5.2026 | 66,906 | -66,906 | — |
| AKKARAJU SRINIVAS | Open Market Purchase | 20.5.2026 | 2,224,147 | +244,300 | $4.83 |
Official FINRA data — the number of shares open in short positions, plus daily short-sale activity.
318,361 shares short as of 2026-09-15 · vs. 345,990 on 2026-08-31
Official biweekly report (FINRA Rule 4560) — no real higher-frequency data exists for this metric.
33.1% of trading volume this week was short selling, vs. 62.4% the prior week
Based on daily short-sale volume (Reg SHO) — a different metric from the open short interest above: this is daily trading volume, not an open position, so it updates weekly rather than biweekly.
Full breakdown of every data type and its source: Data Sources · Methodology